Discovery of 5-HT6 receptor subtype and its exclusive localization within the central nervous system led to extensive investigations of its role in Alzheimer’s disease, schizophrenia, and obesity. In the present study, we present preclinical evaluation of a novel highly-potent and highly-selective 5-HT6R antagonist, AVN-492. The affinity of AVN-492 to bind to 5-HT6R (Ki = 91 pM) was more than three orders of magnitude higher than that to bind to the only other target, 5-HT2BR, (Ki = 170 nM). Thus, the compound displayed great 5-HT6R selectivity against all other serotonin receptor subtypes, and is extremely specific against any other receptors such as adrenergic, GABAergic, dopaminergic, histaminergic, etc. AVN-492 demonstrates good in vitro and in vivo ADME profile with high oral bioavailability and good brain permeability in rodents. In behavioral tests, AVN-492 shows anxiolytic effect in elevated plus-maze model, prevents an apomorphine-induced disruption of startle pre-pulse inhibition (the PPI model) and reverses a scopolamine- and MK-801-induced memory deficit in passive avoidance model. No anti-obesity effect of AVN-492 was found in a murine model. The data presented here strongly indicate that due to its high oral bioavailability, extremely high selectivity, and potency to block the 5-HT6 receptor, AVN-492 is a very promising tool for evaluating the role the 5-HT6 receptor might play in cognitive and neurodegenerative impairments. AVN-492 is an excellent drug candidate to be tested for treatment of such diseases, and is currently being tested in Phase I trials.
IvachtchenkoAV, LavrovskyY, OkunI (2016) AVN-101: A multitarget drug candidate for the treatment of CNS disorders. J Alzheimers Dis53, 583–620.
2.
BenhamúB, Martín-FontechaM, Vázquez-VillaH, PardoL, López-RodríguezML (2014) Serotonin 5-HT6 receptorantagonists for the treatment of cognitive deficiency in Alzheimerdisease. J Med Chem57, 7160–7181.
3.
LiuKC, LiJY, TanHH, DuCX, XieW, ZhangYM, MaWL, ZhangL (2015) Serotonin_6 receptors in the dorsal hippocampus regulatedepressive-like behaviors in unilateral 6-hydroxydopamine-lesionedParkinson’s rats. Neuropharmacology95, 290–298.
4.
NikiforukA (2014) The precognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Rev Neurosci25, 367–382.
5.
RamírezMJ (2013) 5-HT6 receptors and Alzheimer disease. Alzheimer Res Ther5, 15.
6.
MitchellES, NeumaierJF (2005) 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacol Ther108, 320–333.
7.
KarilaD, FreretT, BouetV, BoulouardM, DallemagneP, RochaisC (2015) Therapeutic potential of 5-HT6 receptor antagonists. J Med Chem58, 7901–7912.
8.
GeldenhuysWJ, Van der SchyfCJ (2009) The serotonin 5-HT6 receptor: A viable drug target for treating cognitive deficits in Alzheimer’s disease. Expert Rev Neurother9, 1073–1085.
9.
GeldenhuysWJ, Van der SchyfCJ (2008) Serotonin 5-HT6 receptor antagonists for treatment of Alzheimer’s disease. Curr Top Med Chem8, 1035–1048.
10.
UptonN, ChuangTT, HunterAJ, VirleyDJ (2008) 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics5, 458–469.
11.
IvachtchenkoAV, IvanenkovYA (2013) Small molecule 5-HT6R ligands: A comprehensive insight into their selectivity and activity. Curr Bioact Compd9, 64–100.
12.
HelboeL, EgebjergJ, de JongIE (2015) Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: A double in situ hybridization study. Neuroscience310, 442–454.
13.
MonsmaFJJr, ShenY, WardRP, HamblinMW, SibleyDR (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol43, 320–327.
14.
YuYW, TsaiSJ, LinCH, HsuCP, YangKH, HongCJ (1999) Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport10, 1231–1233.
15.
LaneHY, LinCC, HuangCH, ChangYC, HsuSK, ChangWH (2004) Risperidone response and 5-HT6 receptor gene variance: Genetic association analysis with adjustment for nongenetic confounders. Schizophr Res67, 63–70.
16.
ChiuHJ, WangYC, LiouJH, ChaoCH, LeeH, TsaiKY, LiuWC (2001) Serotonin 6 receptor polymorphism in schizophrenia: Frequency, age at onset and cognitive function. Neuropsychobiology43, 113–116.
17.
ShinkaiT, OhmoriO, KojimaH, TeraoT, SuzukiT, AbeK (1999) Association study of the 5-HT6 receptor gene in schizophrenia. Am J Med Genet88, 120–122.
18.
MasellisM, BasileVS, MeltzerHY, LiebermanJA, SevyS, GoldmanDA, HamblinMW, MacciardiFM, KennedyJL (2001) Lack of association between the T–>C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res47, 49–58.
19.
DubertretC, HanounN, AdèsJ, HamonM, GorwoodP (2004) Family-based association study of the serotonin-6 receptor gene (C267T polymorphism) in schizophrenia. Am J Med Genet B Neuropsychiatr Genet126B, 10–15.
20.
KishiT, FukuoY, OkochiT, KawashimaK, KitajimaT, InadaT, OzakiN, MussoGM, KaneJM, CorrellCU, IwataN (2012) Serotonin-6 receptor gene and schizophrenia: Case-control study and meta-analysis. Hum Psychopharmacol27, 63–69.
21.
MorozovaMA, LepilkinaTA, RupchevGE, BeniashvilyAG, BurminskiyDS, PotaninSS, BondarenkoEV, KazeyVI, LavrovskyY, IvachtchenkoAV (2014) Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: Pilot study. CNS Spectr19, 316–323.
22.
BentleyJC, MarsdenCA, SleightAJ, FoneKC (1997) 5-HT6 antisenseoligonucleotides i.c.v. affects rat performance in thewater maze and feeding. Proceedings of the BritishAssociation for Psychopharmacology Meeting (Cambridge 13-17thJuly), pp. 255.
23.
WoolleyML, BentleyJC, SleightAJ, MarsdenCA, FoneKC (2001) A role for 5HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology41, 210–219.
24.
HealDJ, SmithSL, FisasA, CodonyX, BuschmannH (2008) Selective 5HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther117, 207–231.
25.
FisasA, CodonyX, RomeroG, DordalA, GiraldoJ, MercéR, HolenzJ, VrangN, SorensenRV, HealD, BuschmannH, PauwelsPJ (2006) Chronic 5HT6 receptor modulation by E-6837 induceshypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol148, 973–983.
26.
WilkinsonD, WindfeldK, Colding-JorgensenE (2014) Safety and efficacy of idalopirdine, a 5HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): A randomized, double-blind, placebo-controlled phase 2 trial. Lancet Neurol13, 1092–1099.
27.
GalimbertiD, ScarpiniE (2015) Idalopirdine as a treatment for Alzheimer’s disease. Expert Opin Investig Drugs24, 981–987.
IvachtchenkoAV, IvanenkovYA, VeselovMS, OkunIM (2017) AVN-322 is a safe orally bio-available potent and highly selective antagonist of 5-HT6R with demonstrated ability to improve impaired memory in animal models. Curr Alzheimer Res13, 268–294.
32.
MarcosB, ChuangTT, Gil-BeaFJ, RamirezMJ (2008) Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol155, 434–440.
33.
Clinicaltrials.gov, Long-term safety and tolerability ofidalopirdine (Lu AE58054) as adjunctive treatment to donepezil inpatients with mild-moderate Alzheimer’s disease (STAR Extension), https://clinicaltrials.gov/ct2/show/NCT02079246/.
RiemerC, BorroniE, Levet-TrafitB, MartinJR, PoliS, PorterRH, BösM (2003) Influence of the 5-HT6 receptor on acetylcholine release in the cortex: Pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem46, 1273–1276.
37.
Shirazi-SouthallS, RodriguezDE, NomikosGG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology26, 583–594.
38.
IvachtchenkoAV, GolovinaES, KadievaMG, KysilVM, MitkinOD, TkachenkoSE, OkunIM (2011) Synthesis and structure-activity relationship (SAR) of (5,7-disubstituted 3-phenylsulfonyl-pyrazolo [1,5-a] pyrimidin-2-yl)-methyalamines as potent serotonin 5-HT(6) receptor (5-HT(6)R) antagonists. J Med Chem54, 8161–8173.
39.
OkunI, TkachenkoSE, KhvatA, MitkinO, KazeyV, IvachtchenkoAV (2010) From anti-allergic to anti-Alzheimer’s: Molecular pharmacology of dimebon. Curr Alzheimer Res7, 97–112.
NirogiR, KandikereV, MudigondaK, BhyrapuneniG, MuddanaN, SaralayaR, BenadeV (2009) A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J Neurosci Methods178, 116–119.
45.
(1996) Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC.
46.
WalfAA, FryeCA (2007) The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc2, 322–328.
47.
FoleyAG, MurphyKJ, HirstWD, GallagherHC, HaganJJ, UptonN, WalshFS, ReganCM (2004) The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology29, 93–100.
48.
Bermúdez-RattoniF, Introini-CollisonI, Coleman-MeschesK, McGaughJL (1997) Insular cortex and amygdala lesions inducedafter aversive training impair retention: Effects of degree oftraining. Neurobiol Learn Mem67, 57–63.
49.
HiramatsuM, MurasawaH, NabeshimaT, KameyamaT (1998) Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats. J Pharmacol Exp Ther284, 858–867.
50.
SwerdlowNR, ShoemakerJM, KuczenskiR, BongiovanniMJ, NearyAC, TochenLS, Saint MarieRL (2006) Forebrain D1 function and sensorimotor gating in rats: Effects of D1 blockade, frontal lesions and dopaminedenervation. Neurosci Lett402, 40–45.
51.
LipinskiCA (2004) Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol1, 337–341.
52.
ChanE, McLachlanAJ, PeggM, MacKayAD, ColeRB, RowlandM (1994) Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol36, 563–569.
53.
PressB (2011) Optimization of the Caco-2 permeability assay to screen drug compounds for intestinal absorption and efflux. Methods Mol Biol763, 139–154.
54.
BrownAM (2005) hERG Assay, QT liability, and sudden cardiac death. In Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, MorganrothJ, GussakI, eds. Humana Press, Totowa, NJ, pp. 67–81.
55.
WitchelHJ (2007) The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets11, 321–336.
56.
BenvengaMJ, SpauldingTC (1988) Amnesic effect of the novel anticonvulsant MK-801. Pharmacol Biochem Behav30, 205–207.
57.
SanbergPR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature284, 472–473.
58.
ArntJ, Bang-AndersenB, GraysonB, BymasterFP, CohenMP, DeLappNW, GiethlenB, KreilgaardM, McKinzieDL, NeillJC, NelsonDL, NielsenSM, PoulsenMN, SchausJM, WittenLM (2010) Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment indused by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol13, 1021–1033.
59.
ChuangAT, FoleyA, PughPL, SunterD, TongX, ReganC, DawsonLA, MedhurstAD, UptonN (2006) 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer’s disease. Alzheimers Dement2, 631–632.
60.
RothmanRB, BaumannMH, SavageJE, RauserL, McBrideA, HufeisenSJ, RothBL (2000) Evidence for possible involvement of 5-HT(2B) receptors in cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation102, 2836–2841.
61.
GraviusA, LaszyJ, PietraszekM, SághyK, NagelJ, ChambonC, WegenerN, ValastroB, DanyszW, GyertyánI (2011) Effects of5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for thedetection of cognitive enhancement and antipsychotic-likeactivity. Behav Pharmacol22, 122–135.
62.
LiebenCK, BloklandA, SikA, SungE, van NieuwenhuizenP, SchreiberR (2005) The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology30, 2169–2179.
63.
LindnerMD, HodgesDBJr, HoganJB, OrieAF, CorsaJA, BartenDM, PolsonC, RobertsonBJ, GussVL, GillmanKW, StarrettJEJr, GribkoffVK (2003) An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther307, 682–691.
64.
PouzetB, DidriksenM, ArntJ (2002) Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav71, 635–643.
65.
DudekM, MarcinkowskaM, BuckiA, OlczykA, KołaczkowskiM (2015) Idalopirdine – a small molecule antagonist of 5-HT6with therapeutic potential against obesity. Metab Brain Dis30, 1487–1494.
66.
HirstWD, AbrahamsenB, BlaneyFE, CalverAR, AlojL, PriceGW, MedhurstAD (2003) Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol64, 1295–1308.
67.
BrembergU, CaldirolaP, JensenA, JohanssonG, MottA, SutinL, TejbrantJ (2002) Novel, arylsusfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders. World Patent No. WO2002092585-A1.
68.
MarstonOJ, HeislerLK (2009) Targeting the serotonin 2C receptor for the treatment of obesity and type 2 diabetes. Neuropsychopharmacology34, 252–253.
69.
HalfordJC, HarroldJA (2012) 5-HT(2C) receptor agonists and the control of appetite. Handb Exp Pharmacol209, 349–356.
